177Lu-PSMA-617 radioligand therapy in patient with metastasized castration-resistant prostate cancer: Report of a case and review of the literature

被引：0

作者：

Turpin, L. ^{[1
]}

Calzada, M. C. ^{[1
]}

Yin, J. Zhang ^{[1
]}

Rusu, T. ^{[2
]}

Bruzek, A. Dumont ^{[2
]}

Aveline, C. ^{[1
]}

Sgard, B. ^{[1
]}

Nataf, V. ^{[1
]}

Cussenot, O. ^{[3
]}

Montravers, F. ^{[1
]}

Talbot, J. N. ^{[1
]}

Gauthe, M. ^{[1
,4
]}

机构：

[1] Sorbonne Univ, Hop Tenon, AP HP, Serv Med Nucl, 4 Rue Chine, F-75020 Paris, France

[2] Hop Univ Est Parisien, AP HP, Unite Radiopharm, Pharm Usage Interieur, 4 Rue Chine, F-75020 Paris, France

[3] Sorbonne Univ, Hop Tenon, AP HP, Serv Urol, 4 Rue Chine, F-75020 Paris, France

[4] AP HP, INSERM, UMR 1123, Unite Rech Clin Econ Sante Ile De France, 1 Pl Parvis Notre Dame, F-75004 Paris, France

来源：

MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE | 2019年 / 43卷 / 03期

关键词：

Radioligand therapy; PSMA; Castration-resistant prostate cancer; Lutetium-177; MEMBRANE ANTIGEN; RADIONUCLIDE THERAPY; PET/CT; PREDICTORS; EXPRESSION; EXPERIENCE; DOSIMETRY; LIGAND; SAFETY;

D O I：

10.1016/j.mednuc.2019.03.002

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The prostate-specific membrane antigen (PSMA) is a type II glycoprotein which is over-expressed in prostate cancer tissue, especially in high grade tumours, metastatic disease, as an effect of androgen deprivation therapies and in castrate-resistant prostate cancer (CRPC). Recent studies about radioligand therapy using PSMA ligands labeled with lutetium-177 (Lu-177) in CRPC patients have suggested its interest as a third line of treatment after second generation anti-androgens and chemotherapy by taxane. We present the case of a CRPC patient who was treated by iterative radioligand therapy using PSMA-617 ligand labeled with Lu-177. This case illustrates on the one hand the efficacy of the treatment, and on the other hand the fragility of the patients who are at an advanced stage of their disease. Then we present a short review of the literature on this topic, focusing on the published efficacy and tolerance of Lu-177-PSMA radioligand therapy of CRPC patients. (C) 2019 Elsevier Masson SAS. All rights reserved.

引用

页码：298 / 303

页数：6

共 34 条

[31] Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review [J].

von Eyben, Finn Edler ;

Roviello, Giandomenico ;

Kiljunen, Timo ;

Uprimny, Christian ;

Virgolini, Irene ;

Kairemo, Kalevi ;

Joensuu, Timo .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) :496-508

[32] 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment [J].

Yadav, Madhav Prasad ;

Ballal, Sanjana ;

Tripathi, Madhavi ;

Damle, Nishikant Avinash ;

Sahoo, Ranjit Kumar ;

Seth, Amlesh ;

Bal, Chandrasekhar .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) :81-91

[33] The impact of repeated cycles of radioligand therapy using [177Lu] Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer [J].

Yordanova, Anna ;

Becker, Anja ;

Eppard, Elisabeth ;

Kuerpig, Stefan ;

Fisang, Christian ;

Feldmann, Georg ;

Essler, Markus ;

Ahmadzadehfar, Hojjat .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (09) :1473-1479

[34] Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer [J].

Zhang, Mingfeng ;

Song, Fengju ;

Hunter, David J. ;

Qureshi, Abrar A. ;

Han, Jiali .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2013, 22 (12) :2354-2363

← 1 2 3 4 →